Daratumumab combined with bortezomib, lenalidomide and dexamethasone outperformed bortezomib, lenalidomide and dexamethasone alone in patients with newly diagnosed multiple myeloma, according to results of the phase 3 PERSEUS trial.
The findings — presented at ASH Annual Meeting and Exhibition and published simultaneously in The New England Journal of Medicine — also showed the overall safety profile of daratumumab (Darzalex, Janssen) plus bortezomib (Velcade, Millenium/Takeda), lenalidomide (Revlimid, Bristol Myers Squibb) and dexamethasone to be consistent with the known safety
